96 related articles for article (PubMed ID: 35293070)
1. Socio-economic burden of disease: Survivorship costs for renal cell carcinoma.
Michaeli JC; Michaeli DT; Boch T; Albers S; Michaeli T
Eur J Cancer Care (Engl); 2022 May; 31(3):e13569. PubMed ID: 35293070
[TBL] [Abstract][Full Text] [Related]
2. Socio-economic burden of disease: Survivorship costs for bladder cancer.
Michaeli JC; Boch T; Albers S; Michaeli T; Michaeli DT
J Cancer Policy; 2022 Jun; 32():100326. PubMed ID: 35560269
[TBL] [Abstract][Full Text] [Related]
3. Testicular cancer follow-up costs in Germany from 2000 to 2015.
Michaeli T; Michaeli J; Michaeli D
J Cancer Res Clin Oncol; 2021 Aug; 147(8):2249-2258. PubMed ID: 33885951
[TBL] [Abstract][Full Text] [Related]
4. Prostate cancer follow-up costs in Germany from 2000 to 2015.
Michaeli T; Michaeli D
J Cancer Surviv; 2022 Feb; 16(1):86-94. PubMed ID: 33646503
[TBL] [Abstract][Full Text] [Related]
5. Economic burden of renal cell carcinoma among older adults in the targeted therapy era.
Kale HP; Mays DP; Nadpara PA; Slattum PW; Paul AK; Carroll NV
Urol Oncol; 2019 Jun; 37(6):356.e19-356.e28. PubMed ID: 30846388
[TBL] [Abstract][Full Text] [Related]
6. Rising Economic Burden of Renal Cell Carcinoma among Elderly Patients in the USA: Part II-An Updated Analysis of SEER-Medicare Data.
Shih YT; Xu Y; Chien CR; Kim B; Shen Y; Li L; Geynisman DM
Pharmacoeconomics; 2019 Dec; 37(12):1495-1507. PubMed ID: 31286464
[TBL] [Abstract][Full Text] [Related]
7. The burden of illness associated with renal cell carcinoma in the United States.
Lang K; Danchenko N; Gondek K; Schwartz B; Thompson D
Urol Oncol; 2007; 25(5):368-75. PubMed ID: 17826652
[TBL] [Abstract][Full Text] [Related]
8. Estimated Direct Costs of Renal Cancer by Stage of Disease at Diagnosis and Phase of Its Management: A Whole-Disease Model.
Buja A; De Luca G; Gatti M; Bonaldi F; Gardi M; Bortolami A; Sepulcri M; Bimbatti D; Baldo V; Scioni M; Maruzzo M; Basso U; Zagonel V;
Clin Genitourin Cancer; 2023 Aug; 21(4):e252-e260. PubMed ID: 36906433
[TBL] [Abstract][Full Text] [Related]
9. The Economic Burden of Breast Cancer Survivors in Korea: A Descriptive Study Using a 26-Month Micro-Costing Cohort Approach.
You CH; Kang S; Kwon YD
Asian Pac J Cancer Prev; 2019 Jul; 20(7):2131-2137. PubMed ID: 31350976
[TBL] [Abstract][Full Text] [Related]
10. The social and economic burden of stroke survivors in Italy: a prospective, incidence-based, multi-centre cost of illness study.
Fattore G; Torbica A; Susi A; Giovanni A; Benelli G; Gozzo M; Toso V
BMC Neurol; 2012 Nov; 12():137. PubMed ID: 23150894
[TBL] [Abstract][Full Text] [Related]
11. Healthcare Costs Associated with an Adequate Intake of Sugars, Salt and Saturated Fat in Germany: A Health Econometrical Analysis.
Meier T; Senftleben K; Deumelandt P; Christen O; Riedel K; Langer M
PLoS One; 2015; 10(9):e0135990. PubMed ID: 26352606
[TBL] [Abstract][Full Text] [Related]
12. Direct economic burden of hepatitis B virus related diseases: evidence from Shandong, China.
Lu J; Xu A; Wang J; Zhang L; Song L; Li R; Zhang S; Zhuang G; Lu M
BMC Health Serv Res; 2013 Jan; 13():37. PubMed ID: 23368750
[TBL] [Abstract][Full Text] [Related]
13. The economic burden of cancer in the UK: a study of survivors treated with curative intent.
Marti J; Hall PS; Hamilton P; Hulme CT; Jones H; Velikova G; Ashley L; Wright P
Psychooncology; 2016 Jan; 25(1):77-83. PubMed ID: 26087260
[TBL] [Abstract][Full Text] [Related]
14. Renal cell carcinoma: the population, real world, and cost-of-illness.
Buja A; De Luca G; Gatti M; Cozzolino C; Rugge M; Zorzi M; Gardi M; Sepulcri M; Bimbatti D; Baldo V; Maruzzo M; Basso U; Zagonel V
BMC Urol; 2022 Dec; 22(1):206. PubMed ID: 36536329
[TBL] [Abstract][Full Text] [Related]
15. Health economic changes as a result of implementation of targeted therapy for metastatic renal cell carcinoma: national results from DARENCA study 2.
Soerensen AV; Donskov F; Kjellberg J; Ibsen R; Hermann GG; Jensen NV; Fode K; Geertsen PF
Eur Urol; 2015 Sep; 68(3):516-22. PubMed ID: 25533417
[TBL] [Abstract][Full Text] [Related]
16. Economic burden of resected (stage IB-IIIA) non-small cell lung cancer in France, Germany and the United Kingdom: A retrospective observational study (LuCaBIS).
Andreas S; Chouaid C; Danson S; Siakpere O; Benjamin L; Ehness R; Dramard-Goasdoue MH; Barth J; Hoffmann H; Potter V; Barlesi F; Chirila C; Hollis K; Sweeney C; Price M; Wolowacz S; Kaye JA; Kontoudis I
Lung Cancer; 2018 Oct; 124():298-309. PubMed ID: 29961557
[TBL] [Abstract][Full Text] [Related]
17. Socio-Economic Burden of Myasthenia Gravis: A Cost-of-Illness Study in Bulgaria.
Ignatova V; Kostadinov K; Vassileva E; Muradyan N; Stefanov G; Iskrov G; Stefanov R
Front Public Health; 2022; 10():822909. PubMed ID: 35309194
[TBL] [Abstract][Full Text] [Related]
18. The societal cost of schizophrenia in Sweden.
Ekman M; Granstrom O; Omerov S; Jacob J; Landen M
J Ment Health Policy Econ; 2013 Mar; 16(1):13-25. PubMed ID: 23676412
[TBL] [Abstract][Full Text] [Related]
19. Economic burden of blindness and visual impairment in Germany from a societal perspective: a cost-of-illness study.
Chuvarayan Y; Finger RP; Köberlein-Neu J
Eur J Health Econ; 2020 Feb; 21(1):115-127. PubMed ID: 31493181
[TBL] [Abstract][Full Text] [Related]
20. The Societal Costs of Schizophrenia in Switzerland.
Pletscher M; Mattli R; von Wyl A; Reich O; Wieser S
J Ment Health Policy Econ; 2015 Jun; 18(2):93-103. PubMed ID: 26231000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
